Ever since the discovery that HHT is due to mutations in a single signaling pathway nearly 30 years ago, considerable progress has been made in treating HHT symptoms by blocking the VEGF angiogenic pathway. This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.